223 related articles for article (PubMed ID: 3019202)
1. Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. Centers for Disease Control, Department of Health and Human Services.
Ann Intern Med; 1986 Oct; 105(4):558-9. PubMed ID: 3019202
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 Jun; 35(23):376-8, 383. PubMed ID: 3012309
[No Abstract] [Full Text] [Related]
3. Leads from the MMWR. Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus.
JAMA; 1986 Aug; 256(6):703-4. PubMed ID: 3014176
[No Abstract] [Full Text] [Related]
4. Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus during invasive procedures. Centers for Disease Control, Department of Health and Human Services.
Ann Intern Med; 1986 Jun; 104(6):824-5. PubMed ID: 3010783
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus in the workplace.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1985 Nov; 34(45):681-6, 691-5. PubMed ID: 2997587
[No Abstract] [Full Text] [Related]
6. Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 Mar; 35(10):152-5. PubMed ID: 3005822
[TBL] [Abstract][Full Text] [Related]
7. Immunization of children infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. Recommendations of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services.
Ann Intern Med; 1987 Jan; 106(1):75-8. PubMed ID: 3024547
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus.
Yarchoan R; Redfield RR; Broder S
J Clin Invest; 1986 Aug; 78(2):439-47. PubMed ID: 3016028
[TBL] [Abstract][Full Text] [Related]
9. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 May; 35(20):334-9. PubMed ID: 3010072
[TBL] [Abstract][Full Text] [Related]
10. Human T-lymphotropic virus type III/lymphadenopathy-associated virus antibody testing at alternate sites.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 May; 35(17):284-7. PubMed ID: 3010070
[TBL] [Abstract][Full Text] [Related]
11. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. Centers for Disease Control, U.S. Department of Health and Human Services.
Ann Intern Med; 1986 Aug; 105(2):234-7. PubMed ID: 3014942
[TBL] [Abstract][Full Text] [Related]
12. Human T-lymphotropic virus type III/lymphadenopathy-associated virus: agent summary statement.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 Aug; 35(34):540-2, 547-9. PubMed ID: 3018469
[No Abstract] [Full Text] [Related]
13. Acquired immune deficiency syndrome (AIDS)--recommendations of IMAP.
International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
IPPF Med Bull; 1986 Jun; 20(3):3-4. PubMed ID: 12268332
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence of antibodies against the lymphadenopathy-associated virus/human T-cell lymphotropic virus type III (LAV/HTLV) in a population of homosexuals in Mexico].
Sierra Madero JG; Ponce de León S; Ruiz Palacios G; Tinoco JC; Calva JJ; Zamora EE
Salud Publica Mex; 1986; 28(2):180-5. PubMed ID: 3014666
[No Abstract] [Full Text] [Related]
15. HTLV-III/LAV infection in hemodialysis patients.
Peterman TA; Lang GR; Mikos NJ; Solomon SL; Schable CA; Feorino PM; Britz JA; Allen JR
JAMA; 1986 May; 255(17):2324-6. PubMed ID: 3007792
[TBL] [Abstract][Full Text] [Related]
16. Assessment of screening as a preventive technology: the example of HTLV-III/LAV antibody testing.
Ory HW; Koplan JP; Allen JR
Isr J Med Sci; 1986; 22(7-8):524-8. PubMed ID: 3640749
[TBL] [Abstract][Full Text] [Related]
17. Virologic studies of HTLV-III/LAV in pregnancy: case report of a woman with AIDS.
Rogers MF; Ewing EP; Warfield D; Hardy AM; Emery DR; Wolf GC
Obstet Gynecol; 1986 Sep; 68(3 Suppl):2S-6S. PubMed ID: 3016628
[TBL] [Abstract][Full Text] [Related]
18. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
[TBL] [Abstract][Full Text] [Related]
19. Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III).
Hirsch MS; Wormser GP; Schooley RT; Ho DD; Felsenstein D; Hopkins CC; Joline C; Duncanson F; Sarngadharan MG; Saxinger C
N Engl J Med; 1985 Jan; 312(1):1-4. PubMed ID: 2981106
[TBL] [Abstract][Full Text] [Related]
20. In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV).
Nicholson JK; Cross GD; Callaway CS; McDougal JS
J Immunol; 1986 Jul; 137(1):323-9. PubMed ID: 3011909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
